View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 27, 2020

ExThera blood filter used to treat Covid-19

Hospitals in Germany and Italy have begun using ExThera’s Seraph 100 Microbind Affinity Blood Filter to treat Covid-19.

By Chloe Kent

Hospitals in Germany and Italy have begun using ExThera’s Seraph 100 Microbind Affinity Blood Filter to treat Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Seraph 100 is the only haemoperfusion device approved for the reduction of pathogens in a patient’s bloodstream. Clinical results and virus binding studies suggest that the procedure should help in the treatment of Covid-19.

Whereas first-generation haemoperfusion devices remove only molecules, Seraph 100 is able to lower the concentration of bacteria, viruses and fungi in whole blood. It can significantly reduce the bloodstream concentration of both drug-susceptible and drug-resistant pathogens, the company said.

Improvement of lung function and a rapid reduction of drug-resistant bacterial pathogens has been observed as a result of Seraph 100 treatment.

Further clinical study is needed to confirm the patient benefit of the device in Covid-19, but laboratory studies with cytokines and other pathogens have accurately predicted Seraph 100 clinical results in other bloodstream infections.

ExThera’s scientific advisory board chair Dr Lakhmir Chawla said: “In respiratory diseases caused by viruses, the onset of viremia (virus in the bloodstream) typically heralds severe disease. Reducing viral levels of Covid-19 may allow the body’s immune system to combat the deadly pathogen.”

Clinicians will need to establish whether the virus that causes Covid-19 is present in the bloodstream of infected patients in measurable concentrations, and if so the stage at which this occurs.

Recent publications and clinician feedback have confirmed the presence of the virus on the blood of critically ill Covid-19 patients. The measured binding capacity of a single Seraph 100 filter, about the size of a soda can, is huge in comparison to the amount of virus present in the bloodstream of critically-ill patients.

ExThera president and CEO Robert Ward said: “Since Seraph 100 treatments have also consistently produced improved oxygenation/lung function, we believe that this feature together with virus reduction may be a useful combination for treating Covid-19, while simultaneously treating the dangerous secondary infections that can occur in Covid-19 patients.”

Seraph 100 is CE marked, but has yet to receive US Food and Drug Administration (FDA) approval. However, ExThera has received clinician interest in the use of the technology in the US and hopes for it to be deployed there once it meets FDA guidance.

ExThera also expects to soon deploy the treatment for Covid-19 in France.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU